Olon Spa, based in Italy, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is DAPTOMYCIN, with a corresponding US DMF Number 22923.
Remarkably, this DMF maintains an Active status since its submission on June 15, 2009, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 21, 2014, and payment made on July 03, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II